Drug intelligence / Profile preview

Inflamexa

Development stage: Phase 3
Lead developer: HealthBio
Modality: Small Molecules
Administration: Oral

Overview

Inflamexa is an investigational combination therapy consisting of the CCR5 antagonist maraviroc and the HMG-CoA reductase inhibitor atorvastatin. Developed by HealthBio (formerly IncellDx), the combination is designed as an immune-reset therapy to target chronic inflammatory pathways and immune dysregulation. It is being evaluated in clinical trials for the treatment of post-treatment Lyme disease syndrome (PTLDS) and Long COVID (post-acute sequelae of COVID-19). The therapeutic rationale is based on addressing persistent viral or bacterial proteins (such as Borrelia burgdorferi proteins in monocytes) that drive chronic inflammation and fatigue.

Brand names: Inflamexa
Other names: atorvastatin + maravirocmaraviroc + atorvastatin

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)CCR5 (C-C chemokine receptor type 5)

Beyond the preview

Go deeper on Inflamexa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inflamexa.